Stay updated on Trametinib and Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Trametinib and Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Trametinib and Pembrolizumab in NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe webpage has been updated to include new information about various stages of lung cancer and clinical trial identifiers, while significant details regarding the trial's objectives and treatment protocols have been removed.SummaryDifference68%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4 and changed the date from 2025-03-25 to 2025-01-24.SummaryDifference0.3%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.9%
- Check88 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.9%
Stay in the know with updates to Trametinib and Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Trametinib and Pembrolizumab in NSCLC Clinical Trial page.